Sinus Rhythm Maintenance After Electrical Cardioversion for Atrial Fibrillation in High-Risk Patients — Comparative Efficacy of Antiarrhythmic Medications

Abu-El-Haija, B., Giudici, M. C. (2014). Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion. Clin. Cardiol.,37 (6), 381–385.10.1002/clc.22276664959024700327Search in Google Scholar

Barekatain, A., Razavi, M. (2012). Antiarrhythmic therapy in atrial fibrillation. Indications, guidelines, and safety. Tex. Heart Inst. J.,39 (4), 532–534.Search in Google Scholar

Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y. H., McAnulty Jr., J. H., Zheng, Z. J., Forouzanfar, M. H., Naghavi, M., Mensah, G. A., Ezzati, M., Murray, C. J. L. (2014). Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation,129 (8), 837–847.10.1161/CIRCULATIONAHA.113.005119415130224345399Search in Google Scholar

Dan, G. A., Martinez-Rubio, A., Agewall, S., Boriani, G., Borggrefe, M., Gaita, F., van Gelder, I., Gorenek, B., Kaski, J. C., Kjeldsen, K., et al. (2018). Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace,20 (5), 731–732.10.1093/europace/eux37329438514Search in Google Scholar

Dorian, P., Angaran, P. (2014). β-blockers and atrial fibrillation: Hypertension and other medical conditions influencing their use. Can. J. Cardiol.,30 (5 Suppl), S38–41.10.1016/j.cjca.2013.09.02924530215Search in Google Scholar

Ecker, V., Knoery, C., Rushworth, G., Rudd, I., Ortner, A., Begley, D., Leslie, S. J. (2018). A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clin. Cardiol.,41 (6), 862–870.10.1002/clc.22931648993229878481Search in Google Scholar

Elnaggar, M. N., Jbeili, K., Nik-Hussin, N., Kozhippally, M., Pappachan, J. M. (2018). Amiodarone-induced thyroid dysfunction: A clinical update. Exp. Clin. Endocrinol. Diabetes,126 (6), 333–341.10.1055/a-0577-7574Search in Google Scholar

Faber, T. S., Camm, A. J. (1996). The differentiation of propafenone from other class IC agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Eur. J. Clin. Pharmacol.,51 (3–4), 199–208.10.1007/s0022800501849010685Search in Google Scholar

Falsetti, L., Viticchi, G., Tarquinio, N., Silvestrini, M., Capeci, W., Balloni, A., Catozzo, V., Gentile, A., Pellegrini, F. (2014). CHA₂DS₂-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion. J. Cardiovasc. Med. (Hagerstown),15 (8), 636–641.10.2459/JCM.000000000000013924978663Search in Google Scholar

Galperin, J., Elizari, M. V., Bonato, R., Ledesma, R., Vazquez Blanco, M., Lago, M., Spada, P., Sanchez, J., Piasentin, J., Chiale, P. A. (2014). Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. Cardiol. J.,21 (4), 397–404.10.5603/CJ.a2013.015224293165Search in Google Scholar

Gonna, H., Gallagher, M. M. (2014). The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion. Amer. J. Cardiovasc. Drugs,14 (4), 241–251.10.1007/s40256-014-0064-524604773Search in Google Scholar

Grandi, E., Ripplinger, C. M. (2019). Antiarrhythmic mechanisms of beta blocker therapy Pharmacol. Res.,146, 104274.10.1016/j.phrs.2019.104274Search in Google Scholar

Gwag, H. B., Chun, K. J., Hwang, J. K., Park, S. J., Kim, J. S., Park, K. M., On, Y. K. (2018). Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients. PLoS One,13 (5), e0197352.10.1371/journal.pone.0197352596378529787592Search in Google Scholar

Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Ravens, U., Samol, A., Steinbeck, G., Treszl, A., Wegscheider, K., Breithardt, G. (2012). Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet,380 (9838), 238–246.10.1016/S0140-6736(12)60570-4Search in Google Scholar

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H. C., Heidbuchel, H., Hendriks, J., et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J.,37 (38), 2893–2962.10.1093/eurheartj/ehw210Search in Google Scholar

Klein, H. H., Trappe, H. J. (2015). Cardioversion in non-valvular atrial fibrillation. Dtsch. Arztebl. Int.,112 (50), 856–862.10.3238/arztebl.2015.0856Search in Google Scholar

Lafuente-Lafuente, C., Valembois, L., Bergmann, J. F., Belmin, J. (2015). Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst. Rev.,3, CD005049.10.1002/14651858.CD005049.pub4Search in Google Scholar

Lip, G. Y., Fauchier, L., Freedman, S. B., Van Gelder, I., Natale, A., Gianni, C., Nattel, S., Potpara, T., Rienstra, M., Tse, H. F., Lane, D. A. (2016). Atrial fibrillation. Nat. Rev. Dis. Primers,2, 16016.10.1038/nrdp.2016.16Search in Google Scholar

Lip, G. Y. H., Kamath, S. (2000). Atrial fibrillation (2) Antiarrhythmic agents. The Pharm. J.,264 (7094), 659–663.Search in Google Scholar

Martínez-Brotóns, A. M., Ruiz-Granell, R., Morell, S., Plancha, E., Ferrero, A., Roselló, A., Llácer, A., García-Civera, R. (2006). Therapeutic Success of a prospective cardioversion protocol for persistent atrial fibrillation. Rev. Esp. Cardiol.,59 (10), 1038–1046.10.1157/13093981Search in Google Scholar

Papiris, S. A., Triantafillidou, C., Kolilekas, L., Markoulaki, D., Manali, E. D. (2010). Amiodarone: Review of pulmonary effects and toxicity. Drug Saf.,33 (7), 539–558.10.2165/11532320-000000000-00000Search in Google Scholar

Park, H. S., Kim, Y. N. (2014). Adverse effects of long-term amiodarone therapy. Korean J. Intern. Med.,29 (5), 571–573.10.3904/kjim.2014.29.5.571Search in Google Scholar

Piccini, J. P., Fauchier, L. (2016). Rhythm control in atrial fibrillation. Lancet,388 (10046), 829–840.10.1016/S0140-6736(16)31277-6Search in Google Scholar

Pokorney, S. D., Kim, S., Thomas, L., Fonarow, G. C., Kowey, P. R., Gersh, B. J., Mahaffey, K. W., Peterson, E. D., Piccini, J. P. (2017). Cardioversion and subsequent quality of life and natural history of atrial fibrillation. Amer. Heart J.,185, 59–66.10.1016/j.ahj.2016.10.01828267476Search in Google Scholar

Qin, D., Leef, G., Alam, M.B., Rattan, R., Munir, M. B., Patel, D., Khattak, F., Vaghasia, N., Adelstein, E., Jain, S. K., Saba, S. (2015). Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. J. Amer. Heart Assoc.,4 (4), e001793.10.1161/JAHA.115.001793457993125845930Search in Google Scholar

Rajagopalan, B., Curtis, A. B. (2012). Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation. Postgrad. Med.,124 (6), 26–35.10.3810/pgm.2012.11.261023322136Search in Google Scholar

Roden, D. M. (2000). Antiarrhythmic drugs: from mechanisms to clinical practice. Heart,84 (3), 339–346.10.1136/heart.84.3.339Search in Google Scholar

Saliba, W., Wazni, O. M. (2011). Sinus rhythm restoration and treatment success: Insight from recent clinical trials. Clin. Cardiol.,34 (1), 12–22.10.1002/clc.20826665247821259273Search in Google Scholar

Sardar, M. R., Saeed, W., Kowey, P. R. (2016). Antiarrhythmic drug therapy for atrial fibrillation. Heart Fail. Clin.,12 (2), 205–221.10.1016/j.hfc.2015.08.01726968666Search in Google Scholar

Schilling, R. J. (2010). Cardioversion of atrial fibrillation: The use of antiarrhythmic drugs. Heart,96 (5), 333–338.10.1136/hrt.2008.15581219910286Search in Google Scholar

Singla, S., Karam, P., Deshmukh, A. J., Mehta, J., Paydak, H. (2012). Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation. J. Cardiovasc. Pharmacol. Ther.,17 (1), 12–20.10.1177/107424841039719521335483Search in Google Scholar

Stoschitzky, K., Stoschitzky, G., Lercher, P., Brussee, H. (2017). Oral loading of propafenone: Restoring its role before restoring rhythm-authors’ reply. Europace,19 (11), 1903–1904.10.1093/europace/euw34228062530Search in Google Scholar

Stoschitzky, K., Stoschitzky, G., Lercher, P., Brussee, H., Lamprecht, G., Lindner, W., 2016. Propafenone shows class Ic and class II antiarrhythmic effects. Europace,18 (4), 568–571.10.1093/europace/euv19526056191Search in Google Scholar

Vitali, F., Serenelli, M., Airaksinen, J., Pavasini, R., Tomaszuk-Kazberuk, A., Mlodawska, E., Jaakkola, S., Balla, C., Falsetti, L., Tarquinio, N., Ferrari, R., Squeri, A., Campo, G., Bertini, M. (2019). CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis. Clin. Cardiol.,42 (3), 358–364.10.1002/clc.23147671233130597581Search in Google Scholar

Waks, J. W., Zimetbaum, P. (2017). Drug therapy for rhythm control in atrial fibrillation J. Cardiovasc. Pharmacol. Ther.,22 (1), 3–19.10.1177/107424841665172227260643Search in Google Scholar

Zimetbaum, P. (2017). In the clinic: Atrial fibrillation. Ann. Intern. Med.,166 (5), ITC33–ITC48.10.7326/AITC201703070Search in Google Scholar